HTDK and Suzhou Kangjie Sign Exclusive Strategic Cooperation Agreement to Accelerate the Development of Domestic Ophthalmic and Optometric Equipment

Recently, HTDK and Suzhou Kangjie (Stock Code: 430521) announcedSigning of Exclusive Sales Strategic Cooperation Agreement for the Chinese Mainland, working together to promote high-quality development in the field of optometry and vision care, Huatang Dachang will assist Suzhou Kangjie in building a market-oriented sales team, expanding sales channels, and enhancing market share and industry influence.

 Signing Ceremony Venue

Left: Mr. Zhu Yonglin, Chairman of Suzhou KangjieRight: Ms. Cheng Xuehui, CEO of Hua Tang Da Chang

Suzhou Kangjie is a national high-tech enterprise specializing in the R&D and manufacturing of ophthalmic and optometric diagnostic equipment. Its independently developed series of optometric detection devices include digital slit lamp microscopes, intelligent corneal topographers, and ophthalmic biometers, among others. This strategic partnership will enable both parties to jointly seize the opportunities presented by the rapid development of the optometry sector.Huatang Dachang will leverage its extensive industry experience and exceptional professional service capabilities to build a market-oriented sales team for Suzhou Kangjie, providing comprehensive commercial platform solutions for optometry and professional medical clients.Suzhou Kangjie will focus on the research, development, and production of products, providing more high-quality domestically produced solutions for the rapidly growing ophthalmic optics market.

Zhu Yonglin, Chairman of Suzhou Kangjie, stated:“Suzhou Kangjie highly recognizes Huatang Dachang’s strength and capabilities in the commercialization of high-value medical devices. We sincerely look forward to leveraging this signing as an opportunity to fully capitalize on our respective advantages, broaden the scope of our collaboration, and work hand in hand to promote high-quality development in China’s optometry and ophthalmology sector. I am confident that through our partnership, we will achieve leapfrog growth in the Chinese domestic market and establish a new paradigm for shared development.”

Suzhou Kangjie established the “Lanling” brand trademark in 2005, and in 2014, the company was officially listed on the National Equities Exchange and Quotations (NEEQ), becomingThe First Listed Company in China's Optometry and Vision Care SectorThe company's main products are high-tech proprietary intellectual property products, providing customers with high-quality intelligent and digital ophthalmic diagnostic equipment, remote diagnosis platforms, and information database management systems and services. By 2021, the company had accumulated more than 50 self-developed patents, including 10 invention patents. It has also passed ISO9001 and ISO13485 quality system certifications and obtained CE and FDA international certification certificates.

As China's leading cross-border commercial solutions platform, Huatang Dachang is dedicated to providing professional market access and commercialization solutions for high-value medical devices, currently boasting a network of over 500 distributors and covering more than 1,700 healthcare institutions across China.

Cheng Xuehui, CEO of Hualtang Dachang, stated:“As Chinese intelligent manufacturing continues to rise in the field of ophthalmology, and driven by policy guidelines promoting the replacement of imported equipment with domestically produced alternatives in public hospitals, we are delighted to establish a strategic partnership with Kangjie Medical. With 25 years of dedicated expertise in ophthalmic diagnostic equipment, Kangjie Medical boasts a comprehensive product portfolio and sustained innovation, leading the domestic sector in ophthalmic diagnostics. Huatang Dachang has been engaged in the ophthalmology sector since 2006, accumulating 17 years of extensive experience. We believe that, leveraging Huatang Dachang’s deep and broad distribution network as well as its digital-intelligent management capabilities, this collaboration will inject new momentum into Kangjie’s rapid market penetration and expansion, accelerating the entry of domestically produced products onto the fast track of optometry development. We look forward to combining our respective strengths and working closely together to enhance the accessibility of high-quality medical devices.”

Suzhou Kangjie Medical Co., Ltd. was established in 1998 and has over two decades of history. It is a national high-tech enterprise specializing in the R&D and manufacturing of ophthalmic and optometric diagnostic equipment. The “Lanling” brand trademark was registered in 2005. In 2014, the company was officially listed on the National Equities Exchange and Quotations (NEEQ) (Stock Code: 430521), becoming the first listed company in China’s optometry sector. In 2019, with the approval of the Jiangsu Provincial Department of Science and Technology and the Jiangsu Provincial Department of Finance, the “Jiangsu Provincial Engineering Technology Research Center for Optometry” was established. The company has cultivated an elite technical team specializing in mechanics, optics, and software, dedicated to technological research and services in the field of optometry, gradually establishing and improving intelligent health management guidance standards for optometry. The company’s main products are high-tech proprietary intellectual property rights products, including slit lamp microscopes, digital slit lamp image processing systems, streak retinoscopes, intelligent fundus cameras, intelligent corneal topographers, ophthalmic biometers, intelligent optical coherence tomography (OCT) scanners, myopia laser therapy devices, intelligent autorefractors, and other ophthalmic diagnostic equipment. The company also provides customers with high-quality intelligent and digital ophthalmic diagnostic equipment, remote diagnosis platforms, and information database management systems and services. As of 2023, the company had accumulated 61 self-developed patents, including 10 invention patents. It has passed ISO9001 and ISO13485 quality system certifications and obtained CE and FDA international certification certificates.

Huatang DKSH is China’s leading cross-border commercial solutions platform, providing end-to-end professional commercial solutions for high-value medical devices. Its services cover product registration, import and export, warehousing and distribution, commercial channel management, inventory management, and after-sales management. Huatang DKSH traces its origins to the Chinese operations of DKSH, a Swiss company with a century-long history. In 1996, DKSH established its Shanghai branch in the Shanghai Waigaoqiao Free Trade Zone. In November 2018, Warburg Pincus, a global leading private equity investment firm, completed the 100% equity acquisition of DKSH’s healthcare business in China. In January 2019, the independent company was officially renamed “Huatang DKSH.” After years of rapid development, Huatang DKSH has become a leading provider of commercial solutions in China, focusing on serving global brand owners of high-value medical devices. The company has accumulated extensive experience in serving global brands engaged in cross-border business. It has established long-term partnerships with numerous clients, covering high-value medical device brands across multiple medical specialties, including ophthalmology, in vitro diagnostics (IVD), orthopedics, cardiology, neurology, obstetrics and gynecology, vascular surgery, endocrinology, pulmonology, and high-value medical consumables. Our clients include globally leading brands such as Alcon, MicroVention, Illumina, Smith & Nephew, Roche, Abbott, and Procter & Gamble.